Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.

Abstract

Gene expression profiling has had a considerable impact on our understanding ofbreastcancer biology. Duringthelast decade, 4 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched [HER2-E] and Basal-like) have been identified and intensively studied. In this article, we review and discuss the clinical implications of the 2 non-luminal subtypes (i.e. HER2-E and Basal-like) identified within hormone receptor (HR)-positive disease. After reviewing 32 studies for a total of 13,091 samples, ∼8% and ∼ 15% of early and metastatic HR+/HER2-negative breast cancer, respectively, were found to be non-luminal. Clinically, HR+/HER2-negative/non-luminal subtypes have been associated with estrogen independence, chemo-sensitivity, resistance to CDK4/6 inhibition and poor outcome. Interestingly, EGFR/HER2 tyrosine kinase inhibition might be of value in the HR+/HER2-negative/HER2-E subtype. Finally, the HER2-E subtype within HR+/HER2 + disease represents ∼ 30% and has been associated with anti-HER2 sensitivity, chemo-sensitivity and resistance to CDK4/6 inhibition. In the upcoming years, retrospective and prospective clinical trials evaluating both biomarkers should lead to improvements in patient outcomes.

• Authors: Juan Miguel Cejalvo, Tomás Pascual, Aranzazu Fernández-Martínez, Fara Brasó-Maristany, Roger R Gomis, Charles M Perou, Montserrat Muñoz, Aleix Prat
• Journal: Cancer treatment reviews (Cancer Treat Rev) Vol. 67 Pg. 63-70 (Jun 2018) ISSN: 1532-1967 [Electronic] Netherlands
• PMID: 29763779 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Receptors, Estrogen
• Receptors, Progesterone
• ERBB2 protein, human
• Receptor, ErbB-2
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6

Topics

• Breast Neoplasms (chemistry, drug therapy)
• Cyclin-Dependent Kinase 4 (antagonists & inhibitors)
• Cyclin-Dependent Kinase 6 (antagonists & inhibitors)
• Drug Resistance, Neoplasm
• Female
• Humans
• Prognosis
• Receptor, ErbB-2 (analysis, antagonists & inhibitors)
• Receptors, Estrogen (analysis)
• Receptors, Progesterone (analysis)